本文由小咖机器人翻译整理

期刊来源：Ann Intern Med

原文链接：https://doi.org/10.7326/M24-0581

摘要内容如下：

心脏病学及其所有分支专业继续为各种疾病开发新的治疗策略。在筛选了1300多篇文章后，我们重点介绍了2023年发表的重要心脏病学文章。从预防开始，我们注意到了一些文章，这些文章探讨了Semaglutide对肥胖患者的影响，以及一类药物Bempedoic Acid对心血管结局的影响。我们还研究了比较保守治疗和侵入性治疗体弱老年非ST段抬高型心肌梗死（NSTEMI）患者的新证据。在继发于NSTEMI的心脏骤停患者中，另一篇文章探讨了快速转移到心脏骤停中心的基本原理。STREAM-2（心肌梗死后早期老年患者的策略性再灌注）试验建立在观察老年STEMI患者半剂量溶栓的基础上。心力衰竭患者出院前的治疗重点是指南指导的药物治疗。此外，在稳定的症状性冠状动脉疾病患者中，与有创策略相比，使用冠状动脉计算机断层扫描造影的初始无创检测可能是一种可行的选择。关于设备检测到房颤患者的抗凝策略的更多细节已经浮出水面。最后，治疗二尖瓣和三尖瓣反流的经导管方法也包括在内。

英文原文如下：

Abstracts

Cardiology and all its subspecialties continue to push the envelope in developing new treatment strategies for a wide variety of diseases. After screening more than 1300 articles, we highlight a selection of important cardiology articles published in 2023. Starting with prevention, we note articles that look at the effect of semaglutide in patients with obesity as well as a first-in-class drug, bempedoic acid, on cardiovascular outcomes. We have also examined new evidence comparing conservative management with invasive management of frail, older patients with non-ST-segment elevation myocardial infarction (NSTEMI). In patients with cardiac arrest secondary to NSTEMI, another article examines the rationale for expedited transfer to a cardiac arrest center. The STREAM-2 (Strategic Reperfusion in Elderly Patients Early After Myocardial Infarction) trial builds on looking at half-dose thrombolysis in older populations with STEMI. Emphasis is placed on guideline-directed medical therapy before hospital discharge in those with heart failure. In addition, in patients with stable symptomatic coronary artery disease, initial noninvasive testing using coronary computed tomography angiography may be a viable option compared with invasive strategies. More details have emerged on anticoagulation strategies in those with device-detected atrial fibrillation. Finally, transcatheter approaches to treat both mitral and tricuspid regurgitation have also been included.

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。